Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Nov;119(6):1145–1148. doi: 10.1111/j.1476-5381.1996.tb16016.x

Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae.

A van't Veen 1, J W Mouton 1, D Gommers 1, B Lachmann 1
PMCID: PMC1915913  PMID: 8937717

Abstract

1. The use of pulmonary surfactant has been proposed as a vehicle for antibiotic delivery to the alveolar compartment of the lung. This study investigated survival rates of mice with a respiratory Klebsiella pneumoniae infection treated intratracheally with tobramycin using a natural exogenous surfactant preparation as vehicle. 2. At day 1 after infection, animals were injected intratracheally with 20 microliters of the following solutions: (1) a mixture of surfactant (500 micrograms) and tobramycin (250 micrograms); (2) tobramycin (250 micrograms) alone; (3) surfactant (500 micrograms) alone; and (4) NaHCO3 buffer (control, sham-treatment). A fifth group received no treatment (control). Deaths were registered every 12 h for 8 consecutive days. 3. The results show an increased survival in the group receiving the surfactant-tobramycin mixture compared to the group receiving tobramycin alone (P < 0.05), the group receiving surfactant alone (P < 0.01) and the control groups (P < 0.01). It is concluded that intratracheal instillation of surfactant-tobramycin is superior to tobramycin alone in protecting animals from death due to a respiratory Klebsiella pneumoniae infection.

Full text

PDF
1148

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auten R. L., Notter R. H., Kendig J. W., Davis J. M., Shapiro D. L. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics. 1991 Jan;87(1):101–107. [PubMed] [Google Scholar]
  2. Brain J. D., Knudson D. E., Sorokin S. P., Davis M. A. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res. 1976 Feb;11(1):13–33. doi: 10.1016/0013-9351(76)90107-9. [DOI] [PubMed] [Google Scholar]
  3. Brown R. B., Kruse J. A., Counts G. W., Russell J. A., Christou N. V., Sands M. L. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother. 1990 Feb;34(2):269–272. doi: 10.1128/aac.34.2.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Demaeyer P., Akodad E. M., Gravet E., Schietecat P., Van Vooren J. P., Drowart A., Yernault J. C., Legros F. J. Disposition of liposomal gentamicin following intrabronchial administration in rabbits. J Microencapsul. 1993 Jan-Mar;10(1):77–88. doi: 10.3109/02652049309015314. [DOI] [PubMed] [Google Scholar]
  5. Eijking E. P., van Daal G. J., Tenbrinck R., Luijendijk A., Sluiters J. F., Hannappel E., Lachmann B. Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med. 1991;17(8):475–478. doi: 10.1007/BF01690770. [DOI] [PubMed] [Google Scholar]
  6. Gommers D., Vilstrup C., Bos J. A., Larsson A., Werner O., Hannappel E., Lachmann B. Exogenous surfactant therapy increases static lung compliance, and cannot be assessed by measurements of dynamic compliance alone. Crit Care Med. 1993 Apr;21(4):567–574. doi: 10.1097/00003246-199304000-00019. [DOI] [PubMed] [Google Scholar]
  7. Gortner L., Pohlandt F., Bartmann P. Wirkung eines bovinen Surfactant bei sehr kleinen Frühgeborenen mit konnataler Pneumonie. Monatsschr Kinderheilkd. 1990 May;138(5):274–278. [PubMed] [Google Scholar]
  8. Günther A., Siebert C., Schmidt R., Ziegler S., Grimminger F., Yabut M., Temmesfeld B., Walmrath D., Morr H., Seeger W. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med. 1996 Jan;153(1):176–184. doi: 10.1164/ajrccm.153.1.8542113. [DOI] [PubMed] [Google Scholar]
  9. Harms K., Herting E. Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration. 1994;61(6):348–352. doi: 10.1159/000196367. [DOI] [PubMed] [Google Scholar]
  10. Ilowite J. S., Gorvoy J. D., Smaldone G. C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis. 1987 Dec;136(6):1445–1449. doi: 10.1164/ajrccm/136.6.1445. [DOI] [PubMed] [Google Scholar]
  11. Kharasch V. S., Sweeney T. D., Fredberg J., Lehr J., Damokosh A. I., Avery M. E., Brain J. D. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis. 1991 Oct;144(4):909–913. doi: 10.1164/ajrccm/144.4.909. [DOI] [PubMed] [Google Scholar]
  12. Liu M. Y., Wang L. M., Li E., Enhorning G. Pulmonary surfactant will secure free airflow through a narrow tube. J Appl Physiol (1985) 1991 Aug;71(2):742–748. doi: 10.1152/jappl.1991.71.2.742. [DOI] [PubMed] [Google Scholar]
  13. Mikawa K., Maekawa N., Nishina K., Takao Y., Yaku H., Obara H. Selective intrabronchial instillation of surfactant in a patient with pneumonia: a preliminary report. Eur Respir J. 1993 Nov;6(10):1563–1566. [PubMed] [Google Scholar]
  14. Mukhopadhyay S., Staddon G. E., Eastman C., Palmer M., Davies E. R., Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med. 1994 Mar;88(3):203–211. doi: 10.1016/s0954-6111(05)80348-8. [DOI] [PubMed] [Google Scholar]
  15. Myou S., Fujimura M., Yasui M., Ueno T., Matsuda T. Bronchoalveolar lavage cell analysis in measles viral pneumonia. Eur Respir J. 1993 Nov;6(10):1437–1442. [PubMed] [Google Scholar]
  16. Omri A., Beaulac C., Bouhajib M., Montplaisir S., Sharkawi M., Lagacé J. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1994 May;38(5):1090–1095. doi: 10.1128/aac.38.5.1090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Touw D. J., Brimicombe R. W., Hodson M. E., Heijerman H. G., Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J. 1995 Sep;8(9):1594–1604. [PubMed] [Google Scholar]
  18. Valcke Y. J., Pauwels R. A. Pharmacokinetic evaluation of tobramycin in the alveolar lining fluid of the rat after endotracheal administration. Am Rev Respir Dis. 1991 Nov;144(5):1199–1201. doi: 10.1164/ajrccm/144.5.1199. [DOI] [PubMed] [Google Scholar]
  19. Van Daal G. J., Bos J. A., Eijking E. P., Gommers D., Hannappel E., Lachmann B. Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):859–863. doi: 10.1164/ajrccm/145.4_Pt_1.859. [DOI] [PubMed] [Google Scholar]
  20. van 't Veen A., Gommers D., Mouton J. W., Kluytmans J. A., Krijt E. J., Lachmann B. Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. Br J Pharmacol. 1996 Jun;118(3):593–598. doi: 10.1111/j.1476-5381.1996.tb15442.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. van 't Veen A., Mouton J. W., Gommers D., Kluytmans J. A., Dekkers P., Lachmann B. Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin. Antimicrob Agents Chemother. 1995 Feb;39(2):329–333. doi: 10.1128/aac.39.2.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. van Daal G. J., So K. L., Gommers D., Eijking E. P., Fiévez R. B., Sprenger M. J., van Dam D. W., Lachmann B. Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg. 1991 May;72(5):589–595. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES